Business
Press Release Oct 23 2025
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials".
About this update from Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials". View Attachment
View stock analysis, news, and events for Glenmark Pharmaceuticals Limited